- Pharmacological group: anabolic / androgenic steroids
- Androgen: 20
- Anabolic: 400
- Standard: Methyltestosterone (oral)
- Chemical names: 2а, 17а-dimethyl-Sa-androstan17b-OL-3-OH
- Estrogenic activity: no
- Progesterone activity: no data
Methyldrostonolone, also known as Methasterone, is a potent oral anabolic steroid that has never been available as a prescription drug. Structurally, this steroid is a closely related derivative of drostanolone (Masteron). The difference between these two compounds is only in the addition of the c-17 alpha-methyl group, which ensures high bioavailability of the steroid when taken orally.
These two substances, however, remain very comparable. Both Methyldrostonolone and Drostanolone are non-aromatizing steroids, so both steroids provide favorable anabolic and androgenic ratios. Laboratory analyzes put Superdrol first as it has 4 times the anabolic potential of oral methyltestosterone, displaying only 20% androgenicity (20: 1 ratio, compared to 3: 1). However, the accuracy and actual relevance of these figures still has to be confirmed in the future.
Methyldrostonolone is prized by athletes for its mild anabolic properties, usually accompanied by fat loss and minimal androgenic side effects. Read more here https://anabolicmenu.ws/products/global-anabolic-superdrol-10/.
Methyldrostonolone was first described in 1959. This steroid was developed by the international pharmaceutical giant Syntex, along with other well-known anabolic drugs such as drostanolone propionate and oxymetholone.
Unlike drostanolone and oxymetholone, this steroid, however (at least in its basic form), was never marketed as a drug. It was only marketed for a short period of time as the modified hormone Dimetazine. Dimetazine is made up of two Methyldrostonolone molecules bound together and then metabolically separated to produce free Methyldrostonolone.
Thus, although technically Methyldrostonolone itself was never marketed as a prescription drug, it can be said that it was still used in medical practice. On the other hand, molecularly, Methyldrostonolone remains an understudied substance and has never been approved for human use. Methyldrostonolone was released in early 2005 on the gray market for over-the-counter anabolic steroids in the United States.
The drug was sold as a dietary supplement without restriction, except for some minimum age limit set by the manufacturer. No state or federal law identifies this drug as an anabolic steroid, thus removing all of the measures associated with steroids as a class III controlled substance. This is due to the fact that Methyldrostonolone was not present on the market at the time of the signing of these laws, and simply was not known to legislators.
However, it was illegal to sell it as a dietary supplement, and in late 2005, the FDA discovered the sale of Methyldrostonolone in the sports supplement market. In early 2006, the FDA sent letters to the manufacturer and distributor asking them to stop selling the drug. Since then, Superdrol has disappeared from the market forever.
Methyldrostonolone is a modified form of dihydrotestosterone. It differs:
- the addition of methyl groups on carbon-17-alpha, which helps to protect the hormone when taken orally
- the introduction of a methyl group on carbon-2 (alpha), which significantly increases the anabolic strength of the steroid by increasing its resistance to enzyme metabolism 3 -hydroxysteroid dehydrogenase in skeletal muscle tissue.
Side effects (estrogenic)
Methyldrostonolone is not a fragrance in the human body, and does not exhibit noticeable estrogenic effects. The use of anti-estrogens is optional when using this steroid and gynecomastia should not manifest itself even in sensitive individuals. Estrogen usually affects water retention in the body, while Methyldrostonolone produces a good-looking physique without excessive fluid retention. This makes it a favorable steroid to use during drying cycles where fluid and fat retention are major concerns.
Side effects (androgenic)
Although the steroid is classified as an anabolic, androgenic side effects are common with this substance and can include oily skin, acne, and body / facial hair growth. Anabolic / androgenic steroids can also worsen male pattern baldness. Women should be warned of the potential virilizing effects of anabolic / androgenic steroids.
These can include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Methyldrostonolone is a steroid with a relatively low androgenic relative activity, which makes the threshold for severe androgenic side effects relatively higher than with more androgenic substances such as testosterone, methandrostenolone, or fluoxymesterone.
Please note that Methyldrostonolone is not affected by the 5-alpha reductase enzyme, therefore the relative androgenicity of the substance does not depend on the simultaneous use of finasteride or dutasteride.
Side effects (suppression of testosterone)
All anabolic / androgenic steroids, when taken in doses sufficient to increase muscle mass, suppress endogenous testosterone production. Without the intervention of testosterone stimulating substances, testosterone levels should return to normal within 1-4 months after taking the drug. Note that prolonged hypogonadotropic hypogonadism may develop secondary, requiring medical attention.
Methyldrostanolone has never been approved for human use. Prescribing guidelines are not available. An effective dosage of Methyldrostanolone for physique or performance purposes starts at 10-20 mg per day and is taken no longer than 6-8 weeks. At this level, it provides measurable muscle gain, usually accompanied by fat loss and improved definition.
Don’t expect a 30-pound gain from this agent (its name, which is short for “Super Anadrol”, is more of a marketing ploy than a reality), but many gain more than 10-pound muscle gain when using this drug alone. When determining the optimal daily dose, some find the drug noticeably more effective when used in doses up to 30 mg. However, at such a dosage, the potential hepatotoxicity of the drug must be taken into account.
To avoid further escalation of liver strains, 20 mg of methyldrostonolone daily is recommended to be mixed with non-toxic injectable steroids such as testosterone during the phases of mass gain, or nandrolone or boldenone for drier muscle gain. It also works well for drying cycles where its lack of estrogenicity is appreciated. It is often combined with non-aromatizing injectable steroids such as Primobolan or Parabolan.
Methyldrostonolone has not been approved for human use. Prescribing guidelines are not available. In sports, the oral effective daily dose is in the range of about 2.5 mg per day, in cycles of no more than 4-6 weeks, which minimizes the side effects of virilization.
The main point of controversy is the use of a dosage of 10 mg per capsule in women, which is too high a dose. It will be necessary to open each capsule and divide the powdery contents into 4 separate doses. As with all steroids, virilizing effects are still possible.